NEW YORK (GenomeWeb News) – Gentronix today said that it will provide GlaxoSmithKline with its genotoxicity detection assay, GreenScreen HC, for use in the drug firm's safety evaluation studies.

According to Manchester, UK-based Gentronix, GreenScreen HC is the first human cell-based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay uses green fluorescent protein to detect GADD-45a up regulation, which is a key indicator of DNA damage, said Gentronix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.